Liso-cel in r/r follicular lymphoma shows durable 3-year responses and favourable long-term safety

TKI chemotherapy and ponatinib improve survival outcomes in blast phase CML

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL

Non-TBI conditioning achieves positive results in MRD-negative CAYA B-ALL undergoing allogeneic HCT

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab

Comment: Pirtobrutinib improves PFS in treatment-naïve CLL/SLL compared to bendamustine/rituximab

Glofitamab, venetoclax, and lenalidomide combination shows promising efficacy in high-risk mantle cell lymphoma

ASH 2025: Highlights

Ropeginterferon alfa-2b is evaluated as a disease-modifying option in essential thrombocythemia

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma